 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Entry Inhibitors (Fusion, CCR5, etc.)
Overview/General Research
- Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo - Adverse Effects of Antiretroviral Drugs: Chemokine Coreceptor Antagonists (November 2007)
A table summarizing the most common and most serious adverse events associated with chemokine coreceptor antagonists.
From HIV InSite Knowledge Base Chapter - Adverse Effects of Antiretroviral Drugs: Fusion Inhibitors (November 2007)
A table summarizing the most common and most serious adverse events associated with fusion inhibitors.
From HIV InSite Knowledge Base Chapter - Fuzeon -- A Review of the First Entry Inhibitor (October 2003)
A look at how entry inhibitors and Fuzeon work.
To read PDF, click here
From The Body - Entry Inhibitors: The Bouncers at the Door (Winter 2002/2003)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America - New Drugs: Attacking Chemokine Receptors (March 2002)
In Hopkins HIV Report - New Targets Bring New Challenges (March 2002)
A closer look at integrase and entry inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis - The HIV/AIDS Drug Pipeline: Entry Inhibitors (Summer/Autumn 2002)
From San Francisco AIDS Foundation
  |
  |